- Repare Therapeutics Inc (NASDAQ:RPTX) presented updated data from its ongoing Phase 1/2 TRESR trial of RP-3500 for solid tumors with specific synthetic-lethal genomic alterations.
- The data were featured at the AACR Annual Meeting included monotherapy Phase 1 (Module 1) results from 120 patients.
- RP-3500 monotherapy appeared to be safe and well-tolerated. Mild to moderate anemia was the most common treatment-related adverse event.
- RP-3500 monotherapy resulted in durable clinical benefit across tumor types and genomic alterations. Overall clinical benefit rate (CBR) for all patients was 43% and 47% after PARP inhibitor (PARPi) failure.
- Related: Repare Therapeutics Highlights Early RP-3500 Data In Solid Tumor Patients.
- In the ovarian cancer cohort (n = 20), the overall response (OR) was 25%, including one complete response (CR) and three partial responses (PR).
- CBR was 75%, and median progression-free survival (mPFS) was 35 weeks.
- Clinical benefit was also observed in patients with tumors harboring BRCA1 and BRCA2 genomic alterations (n = 37). ORR was 14%.
- CBR was 43% with an mPFS of 15 weeks in the BRCA1/2 population; in patients specifically with BRCA1 mutations, the CBR was 48%.
- In patients with ATM loss-of-function (LOF) tumors (n = 34), ORR was 9% including one confirmed/unconfirmed response, and two prostate-specific antigen (cPSA) responses.
- CBR in patients with ATM LOF was 44%, with mPFS of 17 weeks.
- Price Action: RPTX shares are down 4.82% at $9.87 during the market session on the last check Tuesday.
Adaptive Biotechnologies Announces New Data Demonstrating The Benefit Of Serial MRD Testing With The clonoSEQ Assay In Patients With Blood Cancers At The 63rd ASH Annual Meeting
Analysis of the MASTER trial (Abstract 481) showed clonoSEQ's ability to measure deep and durable responses and permit treatment discontinuation in multiple myeloma patients
Data in more than 30
